Small risk of breast cancer seen with hormone contraceptives

Modern low-dose birth control pills, available since the 1990s, have fewer side effects than the earliest oral contraceptives
Source: ABC News: Health - Category: Consumer Health News Tags: Health Source Type: news

Related Links:

In 2013 I began searching for ways I could change my career to reduce my workload, but not give up medicine altogether. During that time I took a cruise and looked at various jobs I could do on a cruise ship. One of the jobs I was qualified for, I thought, was to be a Cruise Ship Doctor. After talking with the ship’s doctor to find out what it was like to be the doctor on a ship, I realized that I would enjoy that life. When I arrived back home I sent in an application to a cruise line. I was promptly informed that general surgeons were not qualified to be a ship’s doctor. They only accept physicians who practi...
Source: Kevin, M.D. - Medical Weblog - Category: General Medicine Authors: Tags: Physician Practice Management Primary Care Source Type: blogs
Condition:   Breast Cancer Intervention:   Drug: apatinib+oral etoposide Sponsor:   Chinese Academy of Medical Sciences Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Abstract Developed as an oral anticancer drug to treat estrogen receptor-positive breast cancer, GDC-0810 was shown to be a potent inhibitor of organic anion-transporting polypeptide 1B1 and 1B3 (OATP1B1/1B3) from an in vitro assay. A clinical study was conducted to assess the drug-drug interaction potential between GDC-0810 and pravastatin, which is a relatively selective and sensitive OATP1B1/1B3 substrate. Fifteen healthy female subjects of non-childbearing potential were enrolled in the study. On day 1 in period 1, a single 10-mg dose of pravastatin was administered to all subjects. Following a 4-day washout p...
Source: The Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Authors: Tags: J Clin Pharmacol Source Type: research
ConclusionElevated dNLR appears to be an adverse prognostic factor in hormone receptor-negative early breast cancer.Trial registrationEudraCT: 2005-003108-12 (retrospectively registered 28/06/2005). ClinicalTrials.gov Identifier: NCT00129922 (retrospectively registered 10/08/2005). Results of this study were presented in part at the 2016 ESMO conference October 7 –11, 2016, Copenhagen, Denmark (oral presentation).
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsOnce-daily seviteronel was generally well tolerated in women with and 450  mg QD was chosen as the RP2D.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: Once-daily seviteronel was generally well tolerated in women with and 450 mg QD was chosen as the RP2D. PMID: 29744674 [PubMed - as supplied by publisher]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Breast Cancer Res Treat Source Type: research
Abstract INTRODUCTION: The PI3K/AKT/mTOR pathway is an oncogenic driver in breast cancer (BC). In this multi-center, pre-surgical study, we evaluated the tissue effects of the AKT inhibitor MK-2206 in women with stage I-III BC. MATERIALS AND METHODS: Two doses of weekly oral MK2206 were administered at days - 9 and - 2 before surgery. The primary endpoint was reduction of pAktSer473 in breast tumor tissue from diagnostic biopsy to surgery. Secondary endpoints included changes in PI3K/AKT pathway tumor markers, tumor proliferation (ki-67), insulin growth factor pathway blood markers, pharmacokine...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Clin Transl Oncol Source Type: research
AbstractIntroductionThe PI3K/AKT/mTOR pathway is an oncogenic driver in breast cancer (BC). In this multi-center, pre-surgical study, we evaluated the tissue effects of the AKT inhibitor MK-2206 in women with stage I –III BC.Materials and methodsTwo doses of weekly oral MK2206 were administered at days − 9 and − 2 before surgery. The primary endpoint was reduction of pAktSer473 in breast tumor tissue from diagnostic biopsy to surgery. Secondary endpoints included changes in PI3K/AKT pathway tumor markers, tumor proliferation (ki-67), insulin growth factor pathway blood markers, pharmacokinet...
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
The use of HER2-directed monoclonal antibodies has changed the landscape of patients with HER2-positive breast cancer. Despite the increase in overall survival with the use of agents such as trastuzumab, the drug ’s poor penetration through the blood-brain barrier leaves the brain particularly vulnerable to disease relapse. In contrast, lapatinib, a dual HER2/EGFR small molecule tyrosine kinase inhibitor (TKI), has demonstrated greater penetration through the blood brain barrier, but evidence of its clinic al use in patients with CNS metastases is limited.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Oral Abstract Source Type: research
Dynamic Contrast Enhanced (DCE-) MRI can characterize the microenvironment in solid tumors by determining areas of inadequate or heterogeneous perfusion with hyper-permeable vasculature. As tumor oxygenation is dependent on the microcirculation, the technique may be useful to identify tumor areas with poor blood flow, and therefore, hypoxic microenvironments. Many studies have evaluated DCE-MRI for prediction of breast tumor ’s response to neoadjuvant chemotherapy. However, the analysis has been focused on the entire tumor volume and not accounting for tumor heterogeneity.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Oral Abstract Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Health | Hormones | Oral Cancer